Open Access
Performance standards for antimicrobial susceptibility testing
Reads0
Chats0
TLDR
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards.Abstract:
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards: M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition. The standards contain information about both disk (M02) and dilution (M07 and M11) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treatment of their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tabular information presented here represents the most current information for drug selection, interpretation, and QC using the procedures standardized in the most current editions of M02, M07, and M11. Users should replace the tables published earlier with these new tables. (Changes in the tables since the previous edition appear in boldface type.) Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI supplement M100S (ISBN 1-56238-923-8 [Print]; ISBN 1-56238924-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2016. The data in the interpretive tables in this supplement are valid only if the methodologies in M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition are followed.read more
Citations
More filters
Journal ArticleDOI
Contribution of Resistance-Nodulation-Cell Division Efflux Systems to Antibiotic Resistance and Biofilm Formation in Acinetobacter baumannii
Eun-Jeong Yoon,Yassine Nait Chabane,Sylvie Goussard,Erik Snesrud,Patrice Courvalin,Emmanuelle Dé,Catherine Grillot-Courvalin +6 more
TL;DR: It thus appears that alteration in the expression of efflux systems leads to multiple changes in the relationship between the host and its environment, in addition to antibiotic resistance.
Journal ArticleDOI
Changing Antimicrobial Susceptibility Epidemiology of Helicobacter pylori Strains in Japan between 2002 and 2005
Intetsu Kobayashi,Kazunari Murakami,Mototsugu Kato,Seiichi Kato,Takeshi Azuma,Shin'ichi Takahashi,Naomi Uemura,Tsutomu Katsuyama,Yoshihiro Fukuda,Ken Haruma,Masaru Nasu,Toshio Fujioka +11 more
TL;DR: There is an evolving trend towards increased resistance to clarithromycin with geographical and gender differences as well as between clinical disease conditions in Japan, and current empirical regimens are not based on susceptibility data representative of the general population.
Journal ArticleDOI
Developments in Glycopeptide Antibiotics
Mark A. T. Blaskovich,Karl A. Hansford,Mark S. Butler,Zhiguang Jia,Alan E. Mark,Mark E. Cooper +5 more
TL;DR: Next-generation glycopeptides are now technically well positioned to advance to the clinic, if sufficient funding and market support returns to antibiotic development.
Journal ArticleDOI
Prevalence of gyrA, gyrB, parC, and parE Mutations in Clinical Isolates of Streptococcus pneumoniae with Decreased Susceptibilities to Different Fluoroquinolones and Originating from Worldwide Surveillance Studies during the 1997-1998 Respiratory Season
Mark E. Jones,Daniel F. Sahm,Nele Martin,Sibylle Scheuring,Peter Heisig,Clyde Thornsberry,Karl Köhrer,Franz-Josef Schmitz +7 more
TL;DR: Efflux likely plays a crucial role in reduced susceptibility for new hydrophilic FQs, although the rank order of activity remains independent of mutation type.
Journal ArticleDOI
Prevalence and Clinical Significance of Staphylococcus aureus Small-Colony Variants in Cystic Fibrosis Lung Disease
Silke Besier,Christina Smaczny,Christian von Mallinckrodt,Andreas Krahl,Hanns Ackermann,Volker Brade,Thomas A. Wichelhaus +6 more
TL;DR: The independent risk factors determined here point to the impact of S. aureus SCVs on chronic and persistent infections in advanced CF lung disease.